-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.
-
Persons who do not suffer hyperhidrosis (HID) may be surprised to learn that it has been associated with both occupational and physical impairment, as well as limitations in social interaction.
-
A new class of drug has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) such as mycosis fungoides.
-
A simple questionnaire can identify individuals at risk for chronic kidney disease.
-
-
Left unchecked, stress can have significant effects on your overall health and well-being. Stress can impair your immune system, making you more susceptible to infections, and can increase your risk of cardiovascular disease.
-
Lee R. Kava: Piper methysticum. Altern Med Alert 2007;10(5):49-55.
-
Greenfield RH. Tai gee! Immune augmentation and tai chi. Altern Med Alert 2007;10(5):59-60.
-
Marcolina ST. Nonpharmacologic management of migraine. Altern Med Alert 2007;10(5):55-58.
-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.